Compare BML, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 145,883 Million (Small Cap)
21.00
NA
0.00%
-0.51
6.34%
1.16
Revenue and Profits:
Net Sales:
35,787 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,249 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.38%
0%
-12.38%
6 Months
-6.42%
0%
-6.42%
1 Year
11.98%
0%
11.98%
2 Years
26.65%
0%
26.65%
3 Years
23.02%
0%
23.02%
4 Years
2.1%
0%
2.1%
5 Years
-0.95%
0%
-0.95%
BML, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.40%
EBIT Growth (5y)
-5.14%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
1.12
Tax Ratio
32.71%
Dividend Payout Ratio
74.72%
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
70.82%
ROE (avg)
13.86%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
1.32
EV to EBIT
9.78
EV to EBITDA
5.27
EV to Capital Employed
1.66
EV to Sales
0.68
PEG Ratio
0.68
Dividend Yield
NA
ROCE (Latest)
16.98%
ROE (Latest)
6.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
35,787.00
38,847.00
-7.88%
Operating Profit (PBDIT) excl Other Income
3,775.00
5,524.00
-31.66%
Interest
30.00
30.00
Exceptional Items
0.00
-194.00
100.00%
Consolidate Net Profit
1,249.00
2,402.00
-48.00%
Operating Profit Margin (Excl OI)
34.10%
84.60%
-5.05%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -7.88% vs 3.31% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -48.00% vs -0.99% in Dec 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
150,262.00
143,191.00
4.94%
Operating Profit (PBDIT) excl Other Income
19,544.00
17,081.00
14.42%
Interest
119.00
118.00
0.85%
Exceptional Items
-227.00
-299.00
24.08%
Consolidate Net Profit
8,009.00
6,509.00
23.05%
Operating Profit Margin (Excl OI)
69.40%
65.40%
0.40%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is 4.94% vs 3.79% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 23.05% vs 3.93% in Mar 2025
About BML, Inc. 
BML, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






